



# BEST PRACTICES IN REGENERATIVE MEDICINE

**CARDIOPATCH PROJECT**

**Virtual event**

**June 23, 2021 10:00 AM Madrid**



**ZOOM platform**

Link: <https://unav.zoom.us/j/95703457456?pwd=VjNac1pUekllM3owYmltK0lsNEExqZz09>

Meeting ID: 957 0345 7456

Passcode: 442924



## AGENDA

### BEST PRACTICES IN REGENERATIVE MEDICINE

#### WELCOME AND TALKS

**Description:**

In this event we will overview best practices in stem-cell therapy and discuss the hurdles that need to be overcome to implement cell therapy in the clinical setting with special focus on regenerative medicine.

ENTITY	SPEAKERS	TITLE	TIME
HSCSP	Javier Briones	CAR-T cell therapy	10:00 – 10:15
FIRHSCSP	Gemma Arderiu	Obtention and miRNA regulation of ASCs to induce endothelial differentiation for therapeutic application	10:15 – 10:30
IBEC	Nuria Monserrat	Tissue Engineering: growing opportunities and clinical challenges	10:30 – 10:45
Discussion			10:45 – 11:15





## CARDIOPATCH PROJECT

### Regenerative Medicine and 3D Printing Technology in the Treatment of Myocardial Infarction

Co-funded by the EU Interreg Sudoe Programme, via the European Regional Development Fund (ERDF), CARDIOPATCH project is investigating new treatments for myocardial infarction and aims to provide solutions to improve patients' quality of life. Coordinated by [the University Clinic of Navarra](#) (CUN), the project involves nine centres from Spain, France and Portugal with expertise in cardiology, cell therapy, nanotechnology, 3D printing, bioengineering and technology transfer.

CARDIOPATCH will focus on developing a “smart” patch able to regenerate tissues damaged by infarction. With this aim, the project partners will work on a collagen fibre patch impregnated with mesenchymal stem cells taken from body fat. The patch is currently in the first phase of a clinical trial on patients with chronic ischaemic cardiomyopathy. The CARDIOPATCH team aims to optimise the therapeutic benefit of the patch using genetic modification and cell reprogramming techniques. The regenerative capacity of the patch's collagen membrane will also be enhanced by adding cardiomyocytes, which are the cells that make up the cardiac muscle. In addition to therapeutically validating the new patch, the project also aims to develop another two biomedical products: a roll-up 3D device which will allow the patch implantation in the heart through less invasive methods, and a 3D system to generalize the patch' production and streamline transport.

In addition to developing advanced solutions, another aim of the CARDIOPATCH project is to create an “Excellence Network” to foster R&D and innovation in the biomedical sector in South West Europe, with the intention of extending industry 4.0 technologies into the healthcare sector. The CARDIOPATCH Excellence Network will foster cooperation with public authorities in participating regions by rolling out tools and services to keep them informed on the latest developments in regenerative cardiac medicine, aiding the strategic decision-making process. The project also aims to involve society. To do this, it will organise a series of outreach activities and training workshops on breakthroughs in research.

With a total budget of €1.419 million, the CARDIOPATCH consortium is made up of [CUN](#), [CIMA University of Navarra](#), via the Foundation for Applied Medical Research, the [Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau](#), [LEARTIKER](#) technology centre, communication agency [GUK](#), [Centre Hospitalier Universitaire de Toulouse](#), the University of Montpellier (UM) - [Institut des Biomolécules Max Mousseron \(IBMM\)](#), [Genlbet Biopharmaceuticals](#) and the [Instituto de Biología Experimental e Tecnológica](#).

Watch this video and know more about CARDIOPATCH network!

